{
    "nctId": "NCT05287308",
    "briefTitle": "Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study",
    "officialTitle": "Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "5-year invasive disease-free survival (IDFS) rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged from 18 to 70 years old;\n2. Histologically confirmed as invasive breast cancer;\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n4. Participants achieved complete tumor resection by radical mastectomy, modified radical mastectomy or breast-conserving surgery with negative margins;\n5. AC-T adjuvant chemotherapy is planned after breast cancer surgery;\n6. Participants with HER-2 negative breast cancer at high risk of recurrence who meet any of the following conditions: 1) HR positive, and \u22654 positive lymph nodes or 1-3 positive lymph nodes with other risk of recurrence \\[such as high Ki67 expression (\u226520%), T \\> 2 cm, age \\< 35 years, lymphovascular invasion, grade 3 histology\\]; 2) HR negative with positive lymph node or T \\> 2 cm;\n7. LVEF \u2265 50%;\n8. Participants had good compliance with the planned treatment and follow-up, understood the study procedures of this study, and signed informed consent form.\n\nExclusion Criteria:\n\n1. In the past and present, participants with severe cardiac disease or discomfort , including but not limited: 1) High-risk uncontrolled arrhythmia, atrial tachycardia (heart rate \\> 100/min in resting state), significant ventricular arrhythmia (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2 \\[Mobitz 2\\] atrioventricular block or third-degree atrioventricular block); 2) Angina pectoris requiring anti-angina medication; 3) Clinically significant valvular heart disease; 4) ECG showing transmural myocardial infarction; 5) Uncontrolled hypertension (eg systolic blood pressure \\> 180mm Hg or diastolic blood pressure \\> 100mmHg); 6) Myocardial infarction; 7) Congestive heart failure;\n2. Participants who have received prior any systematic treatment for breast cancer;\n3. Participants with bilateral invasive breast cancer;\n4. Breast cancer with distant metastasis;\n5. Grade 2 or higher Sensory or motor neurotoxicity was present as assessed by CTCAE V5.0;\n6. Participants have the following serious illnesses or medical conditions, including but not limited: 1) History of serious neurological or psychiatric disorders, including psychosis, dementia, or epilepsy, that prevent understanding and informed consent; 2) Active uncontrolled infection; 3) Active peptic ulcer, unstable diabetes;\n7. Previous or current existence of other malignant tumors other than breast cancer;\n8. Severe liver and kidney dysfunction;\n9. The presence of any myelodysplastic and other hematopoietic disorders;\n10. Participants who are known to be allergic to the active or other components of the study treatment;\n11. Participants who are pregnant, breastfeeding, or refuse to use adequate contraception prior to study entry and for the duration of study participation;\n12. Participants who were judged by the investigator to be unsuitable for this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}